Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Dermata Therapeutics, Inc. (DRMA : NSDQ)
 
 • Company Description   
Dermata Therapeutics, Inc. is a clinical-stage biotechnology company focusing on the treatment of medical and aesthetic skin conditions.

Number of Employees: 8

 
 • Price / Volume Information   
Yesterday's Closing Price: $0.66 Daily Weekly Monthly
20 Day Moving Average: 79,604 shares
Shares Outstanding: 6.38 (millions)
Market Capitalization: $4.24 (millions)
Beta: 0.54
52 Week High: $3.79
52 Week Low: $0.57
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -5.68% -10.79%
12 Week -15.74% -29.31%
Year To Date -50.81% -53.93%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
3525 DEL MAR HEIGHTS ROAD SUITE 322
-
SAN DIEGO,CA 92130
USA
ph: 858-800-2543
fax: -
sproehl@dermatarx.com http://www.dermatarx.com
 
 • General Corporate Information   
Officers
Gerald T. Proehl - President; Chief Executive Officer and Chairman
Kyri K. Van Hoose - Chief Financial Officer
Wendell Wierenga - Director
Mary Fisher - Director
Steven J. Mento - Director

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 249845405
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/25
Next Expected EPS Date: 08/06/25
Share - Related Items
Shares Outstanding: 6.38
Most Recent Split Date: 5.00 (0.07:1)
Beta: 0.54
Market Capitalization: $4.24 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/06/25  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 0.55
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: 93.61%
vs. Previous Quarter: -%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
06/30/25 - -
03/31/25 - -270.81
12/31/24 - -366.01
ROA
06/30/25 - -
03/31/25 - -179.96
12/31/24 - -238.14
Current Ratio
06/30/25 - -
03/31/25 - 3.70
12/31/24 - 1.79
Quick Ratio
06/30/25 - -
03/31/25 - 3.70
12/31/24 - 1.79
Operating Margin
06/30/25 - -
03/31/25 - -
12/31/24 - -
Net Margin
06/30/25 - -
03/31/25 - -
12/31/24 - -
Pre-Tax Margin
06/30/25 - -
03/31/25 - -
12/31/24 - -
Book Value
06/30/25 - -
03/31/25 - 1.21
12/31/24 - 0.62
Inventory Turnover
06/30/25 - -
03/31/25 - -
12/31/24 - -
Debt-to-Equity
06/30/25 - -
03/31/25 - 0.00
12/31/24 - 0.00
Debt-to-Capital
06/30/25 - -
03/31/25 - 0.00
12/31/24 - 0.00
 

Powered by Zacks Investment Research ©